Faculty

Institution

Unit

Venue

John N. Papadopoulos

Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Palliative, Rehabilitation And Integrative Medicine

Department Of Neurosurgery

Division Of Surgery

Department Of Urology

Department Of Neurosurgery

Division Of Surgery

The University of Texas MD Anderson Cancer Center

John N. Papadopoulos is currently serving as a Neurosurgery Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

John N. Papadopoulos

The University of Texas MD Anderson Cancer Center

Professor

You can click a keyword to filter the displayed items

urology oncology prostate cancer surgical oncology genitourinary cancers cancer care cancer treatment surgery radiation oncology cancer research prostatic disease bladder cancer neurology metastasis pharmacotherapy cancer immunotherapy molecular cancer jama oncology reconstructive microsurgery immune checkpoint inhibitors minimally invasive procedures active surveillance therapeutic targets clinical research cancer discovery medicinal research cancer letter surgical pathology cancer management robot-assisted surgery phase ii trial resuscitation surgical education dermatological treatment future medicinal chemistry oncogenes cancer cells urological research continuous monitoring disease classification surgical care post-operative care clinical surgery surgical training clinical radiation oncology endocrine-related cancers cancer biology disease surveillance short-term variability g protein-coupled receptor renal pathophysiology cancer risk treatment options novel therapies therapeutic efficacy cancer growth ctla-4 blockade intermediate term outcomes neoadjuvant platelet high risk androgen ablation disease reclassification risk favourable-risk prostate cancer frequent monitoring stringent criteria complex surgery prospective pilot study abiraterone acetate neoadjuvant apalutamide salvage topical therapy gynecologic oncology pathology urogynecology pediatric urology thoracic oncology nephrology kidney cancer microsurgery radiology outcomes research gynecologic cancers neurosurgery anatomical pathology palliative medicine pain management translational medicine palliative care orthopedic surgery sexual medicine gastrointestinal surgery sarcoma spinal cord injury hepatology brain tumor research orthopaedic surgery gynecology cancer imaging histopathology internal medicine medicine neuro-oncology

Notable Scholarly Works

Notable Federal Grants

Collaborators

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy With Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. European Urology (2026)

metastasisurologyprostatic diseasemedicineoncologygenitourinary cancersdefinitive treatmentprimary tumorcancer carecancer treatmentphase 2prostate cancerpharmacotherapyclinical trials

Does Inclusion of Grade Group 1 Core Volume at Time of Fusion Biopsy Impact Rate of Adverse Pathology at Radical Prostatectomy?. Urologic Oncology Seminars and Original Investigations (2025)

urologysurgical oncologyprostatic diseaseoncologyradiation oncologygenitourinary cancerscancer caresurgical pathologyoutcomes researchprostate cancer

Grade Group 1 Core Volume at Time of Biopsy is Not Associated With Rate of Adverse Pathology at Radical Prostatectomy. JU Open Plus (2025)

urologysurgical oncologyprostatic diseaseoncologyradiation oncologygenitourinary cancersradical prostatectomycore volumecancer caresurgical pathologyprostate cancergrade group 1

A Phase II Trial of Apalutamide for Intermediate‐Risk Prostate Cancer and Molecular Correlates. British Journal of Urology (2024)

Andrew W. HahnGaniraju C. ManyamBrian F. ChapinMiao ZhangYao YuCurtis A. PettawayLisly CheryLouis L. PistersJohn F. WardJustin R. GreggJohn PapadopoulosAshish M. KamatMarisa LozanoAnh HoangBradley BroomXuemei WangChad D. HuffChristopher J. LogothetisPatricia TroncosoPatrick G. PiliéJohn W. Davis

urologyphase ii trialoncologyintermediate-risk prostate cancerpharmacologyprostate cancermolecular correlatesneurologyclinical trials

Robotic or Open Superficial Inguinal Lymph Node Dissection as Staging Procedures for Clinically Node Negative High Risk Penile Cancer. Urologic Oncology Seminars and Original Investigations (2024)

robot-assisted surgeryurologysurgical oncologystaging proceduresoncologysurgeryreconstructive microsurgerymicrosurgeryminimally invasive procedures

The Association of Body Mass Index With Tumor Aggression Among Men Undergoing Radical Prostatectomy. Urologic Oncology Seminars and Original Investigations (2024)

Justin R. GreggResa MagillAndrew M. FangBrian F. ChapinJohn W. DavisMehrad AdibiLisly ChéryJohn PapadopoulosCurtis PettawayLouis PistersJohn F. WardAndrew W. HahnCarrie R. DanielJerusha BhaskaranKeyi ZhuMireya GuerreroMiao ZhangPatricia Troncoso

urologysurgerytumor aggressionradical prostatectomyprostate cancerbody mass index

241 Immune Checkpoint Blockade (Icb) in Brain Metastases (Bm) From Advanced Small Cell Urothelial Cancer (Ascuc). Regular and Young Investigator Award Abstracts (2021)

Nathaniel WilsonOmar AlhalabiElshad HasanovLianchun XiaoJohn PapadopoulosMatthew CampbellAmishi ShahJianjun GaoPaul CornAna AparicioJennifer WangBogdan CzerniakCharles GuoChristopher LogothetisJing LiSeungtaek ChoiChad TangNizar TannirArlene Siefker-Radtke

cancer immunotherapycancer biologypharmacologymetastasisurologycellular therapyoncologycancer researchimmune checkpoint blockadecancer carecancer treatmentbrain tumor researchneurologybrain metastasesgenitourinary cancersneuro-oncologyimmune checkpoint inhibitorsmedicinal researchcancer managementexperimental medicine

Abiraterone Acetate Plus Prednisone in Non-Metastatic Biochemically Recurrent Castration-NaïVe Prostate Cancer. European Journal of Cancer (2021)

urologyprostatic diseaseabiraterone acetateoncologymolecular cancergenitourinary cancerscancer carepharmacologytherapeutic targetsprostate cancercancer discovery

Gfr Fluctuation Induced by Neoadjuvant Chemotherapy Correlates With Pathologic Stage of Upper Tract Urothelial Carcinoma. European Urology (2021)

P.J. HensleyT. MiestM. AdibiM. CampbellA. ShahL. CherryJ. PapadopoulosA. Siefker-RadtkeJ. GaoC. GuoB. CzerniakN. NavaiA. KamatC. DinneyS. Matin

urologycancer researchoncologygenitourinary cancersshort-term variabilityg protein-coupled receptorcancer careimmunologycancer treatmentrenal pathophysiologycarcinogenesisgfr fluctuationpathologypathologic stage

Oncologic Outcomes and Subsequent Treatment Following Organ Sparing Surgery for Penile Carcinoma: The University of Texas M.D. Anderson Cancer Center Experience. Urologic Oncology Seminars and Original Investigations (2021)

urologysurgical oncologypenile carcinomaoncologyoncologic outcomessurgerygenitourinary cancerstexas m.dcancer managementcancer careoutcomes research

1
2
3
4
10 / page

John N. Papadopoulos

Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Palliative, Rehabilitation And Integrative Medicine

Department Of Neurosurgery

Division Of Surgery

Department Of Urology

Department Of Neurosurgery

Division Of Surgery

The University of Texas MD Anderson Cancer Center

John N. Papadopoulos is currently serving as a Neurosurgery Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

John N. Papadopoulos

The University of Texas MD Anderson Cancer Center

Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy With Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. European Urology (2026)

metastasisurologyprostatic diseasemedicineoncologygenitourinary cancersdefinitive treatmentprimary tumorcancer carecancer treatmentphase 2prostate cancerpharmacotherapyclinical trials

Does Inclusion of Grade Group 1 Core Volume at Time of Fusion Biopsy Impact Rate of Adverse Pathology at Radical Prostatectomy?. Urologic Oncology Seminars and Original Investigations (2025)

urologysurgical oncologyprostatic diseaseoncologyradiation oncologygenitourinary cancerscancer caresurgical pathologyoutcomes researchprostate cancer

Grade Group 1 Core Volume at Time of Biopsy is Not Associated With Rate of Adverse Pathology at Radical Prostatectomy. JU Open Plus (2025)

urologysurgical oncologyprostatic diseaseoncologyradiation oncologygenitourinary cancersradical prostatectomycore volumecancer caresurgical pathologyprostate cancergrade group 1

A Phase II Trial of Apalutamide for Intermediate‐Risk Prostate Cancer and Molecular Correlates. British Journal of Urology (2024)

urologyphase ii trialoncologyintermediate-risk prostate cancerpharmacologyprostate cancermolecular correlatesneurologyclinical trials

Robotic or Open Superficial Inguinal Lymph Node Dissection as Staging Procedures for Clinically Node Negative High Risk Penile Cancer. Urologic Oncology Seminars and Original Investigations (2024)

robot-assisted surgeryurologysurgical oncologystaging proceduresoncologysurgeryreconstructive microsurgerymicrosurgeryminimally invasive procedures

The Association of Body Mass Index With Tumor Aggression Among Men Undergoing Radical Prostatectomy. Urologic Oncology Seminars and Original Investigations (2024)

urologysurgerytumor aggressionradical prostatectomyprostate cancerbody mass index

241 Immune Checkpoint Blockade (Icb) in Brain Metastases (Bm) From Advanced Small Cell Urothelial Cancer (Ascuc). Regular and Young Investigator Award Abstracts (2021)

Abiraterone Acetate Plus Prednisone in Non-Metastatic Biochemically Recurrent Castration-NaïVe Prostate Cancer. European Journal of Cancer (2021)

urologyprostatic diseaseabiraterone acetateoncologymolecular cancergenitourinary cancerscancer carepharmacologytherapeutic targetsprostate cancercancer discovery

Gfr Fluctuation Induced by Neoadjuvant Chemotherapy Correlates With Pathologic Stage of Upper Tract Urothelial Carcinoma. European Urology (2021)

P.J. HensleyT. MiestM. AdibiM. CampbellA. ShahL. CherryJ. PapadopoulosA. Siefker-RadtkeJ. GaoC. GuoB. CzerniakN. NavaiA. KamatC. DinneyS. Matin

urologysurgical oncologypenile carcinomaoncologyoncologic outcomessurgerygenitourinary cancerstexas m.dcancer managementcancer careoutcomes research

1
2
3
4
10 / page